Corporate News-Alpha Biopharma

Phone: +86 21 63862192
Mailbox: info@alphabiopharma.com
Shanghai: Unit 04-08, 5F, Platinum Building, No.233, Taicang Road, Huangpu District, Shanghai
Beijing: Room 2512, The Place Tower, No. 9 Guanghua Road, Chaoyang District, Beijing

Share :

NEWS

: Ongoing Clinical Challenge: T...
Professor Wu Yilong will bring EVEREST study landing in this year's A...
view more

: Ongoing Clinical Challenge: T...
EGFR-TKI therapy for EGFR-mutated NSCLC patients with CNS met...
view more

: CDE Accepted Alpha Biophar...
Zorifertinib, a next-generation EGFR-TKI specially designed to treat adv...
view more

: Wugen Presents Data on WU-N...
WU-NK-101 overcomes limitations encountered with other adoptive cell therapi...
view more

: Wugen Presents Data Supporti...
Genetic tumor microenvironment (TME) signature identified as highly predicti...
view more

: Wugen Receives U.S. FDA F...
Wugen today announced that the U.S. Food and Drug Administration (FDA) ...
view more

: Wugen Presents New Preclinic...
Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of o...
view more

: Wugen Announces First Patien...
WU-CART-007 granted FDA Orphan Drug Designation for the treatment of...
view more

: Immunotherapy product developme...
On September 18, 2021, Alpha Biopharma announced that its immunotherapy prod...
view more

1
2